ARTICLE | Company News
Celltrion Inc, J&J, Merck autoimmune news
February 23, 2015 8:00 AM UTC
Johnson & Johnson said the U.S. Patent and Trademark Office issued a final rejection following the re-examination of U.S. Patent No. 6,284,471, which covers the pharma’s autoimmune drug Remicade infl...